A case study discussing why post-approval changes present a very low risk, and therefore can be downgraded from a prior-approval to a notification after implementation and managed in the PQS with immediate implementation effect.
Séverine Allard
Advertisement
Séverine Allard is Head of Global Regulatory Affairs at RegCMC Vaccines.
Articles by Séverine Allard
Advertisement
Latest Updated Articles
- Industry 1VQ Solutions: Changes That Bring an Additional Restriction on the Product Compared to Registered Conditions
Published: August 16th 2022 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
